Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood - Related Studies

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

This study is ongoing, but not recruiting participants.

Study NCT00030667. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Gastrointestinal Stromal Tumor
		Metastatic Cancer
		Neuroblastoma
		Sarcoma

2	Additional conditions recognized in this trial
		Gastrointestinal Stromal Tumors
		Neoplasm Metastasis

3	More general conditions related to this trial
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Connective and Soft Tissue
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neoplasms, Neuroepithelial
		Neoplastic Processes
		Neuroectodermal Tumors
		Neuroectodermal Tumors, Primitive
		Neuroectodermal Tumors, Primitive, Peripheral
		Pathologic Processes

4	Interventions listed in this trial
		imatinib mesylate

5	Additional drug interventions recognized in this trial
		Imatinib

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protein Kinase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Children's Oncology Group
		National Cancer Institute (NCI)